Myelotoxicity from chemotherapy.
Publication
, Journal Article
Daniel, D; Crawford, J
Published in: Semin Oncol
February 2006
Myelosuppression continues to be a major dose-limiting toxicity for most chemotherapy regimens. While the development of growth factors has changed the approach to myelosuppression, costs remain high and can be measured both in terms of quality of life (QOL) and economic outcomes. Growing data suggest that there may also be effects on response and survival in some tumors. This review will highlight the incidence, effect, and treatment/prevention of myelosuppression and briefly discuss the questions that remain.
Duke Scholars
Published In
Semin Oncol
DOI
ISSN
0093-7754
Publication Date
February 2006
Volume
33
Issue
1
Start / End Page
74 / 85
Location
United States
Related Subject Headings
- Thrombocytopenia
- Risk Factors
- Quality of Life
- Oncology & Carcinogenesis
- Neutropenia
- Neoplasms
- Middle Aged
- Humans
- Clinical Trials as Topic
- Bone Marrow
Citation
APA
Chicago
ICMJE
MLA
NLM
Daniel, D., & Crawford, J. (2006). Myelotoxicity from chemotherapy. Semin Oncol, 33(1), 74–85. https://doi.org/10.1053/j.seminoncol.2005.11.003
Daniel, Davey, and Jeffrey Crawford. “Myelotoxicity from chemotherapy.” Semin Oncol 33, no. 1 (February 2006): 74–85. https://doi.org/10.1053/j.seminoncol.2005.11.003.
Daniel D, Crawford J. Myelotoxicity from chemotherapy. Semin Oncol. 2006 Feb;33(1):74–85.
Daniel, Davey, and Jeffrey Crawford. “Myelotoxicity from chemotherapy.” Semin Oncol, vol. 33, no. 1, Feb. 2006, pp. 74–85. Pubmed, doi:10.1053/j.seminoncol.2005.11.003.
Daniel D, Crawford J. Myelotoxicity from chemotherapy. Semin Oncol. 2006 Feb;33(1):74–85.
Published In
Semin Oncol
DOI
ISSN
0093-7754
Publication Date
February 2006
Volume
33
Issue
1
Start / End Page
74 / 85
Location
United States
Related Subject Headings
- Thrombocytopenia
- Risk Factors
- Quality of Life
- Oncology & Carcinogenesis
- Neutropenia
- Neoplasms
- Middle Aged
- Humans
- Clinical Trials as Topic
- Bone Marrow